<DOC>
	<DOCNO>NCT00007891</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Peripheral stem cell transplantation bone marrow transplantation may able replace immune cell destroy monoclonal antibody therapy use kill tumor cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy follow bone marrow peripheral stem cell transplantation treat patient metastatic breast cancer .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 label , humanize monoclonal antibody BrE-3 give combination indium In 111 labeled , humanized monoclonal antibody BrE-3 follow autologous bone marrow peripheral blood stem cell transplantation patient metastatic breast cancer . - Determine hematopoietic engraftment patient treat regimen . - Determine ability indium In 111 labeled , humanized monoclonal antibody BrE-3 image metastatic disease patient . - Determine pharmacokinetics regimen patient . - Determine preliminary antitumor response patient treat regimen . OUTLINE : This dose escalation study yttrium Y 90 label , humanize monoclonal antibody BrE-3 ( Y90 huMOAB BrE-3 ) . Patients receive Y90 huMOAB BrE-3 indium In 111 labeled , humanized monoclonal antibody BrE-3 IV 1-2 hour day -14 . Patients undergo autologous bone marrow peripheral blood stem cell transplantation day 0 . Patients also receive filgrastim ( G-CSF ) IV begin day 0 continue blood count recover . Cohorts 3-6 patient receive escalate dos Y90 huMOAB BrE-3 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Patients follow every 3-4 month 1 year least annually thereafter . PROJECTED ACCRUAL : Approximately 3-30 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic breast cancer BrE3 positive Relapsed refractory disease tumor progression effective therapy allow Measurable evaluable disease Received least one prior chemotherapy regimen metastatic disease least one following : Chemotherapy refractory liver metastases 2 cm Multiple nonresectable liver metastasis Brain metastasis Prior highdose chemotherapy Relapse within prior radiotherapy field Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Over 18 Sex : Male female Menopausal status : Not specify Performance status : 01 Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm3 Absolute neutrophil count great 1,000/mm3 Platelet count great 100,000/mm3 Hepatic : Bilirubin le 2 time normal SGOT/SGPT le 2 time normal Renal : Creatinine clearance great 60 mL/min Cardiovascular : LVEF great 45 % MUGA scan Pulmonary : DLCO FEV 1.0 great 60 % predict Other : Not pregnant Negative pregnancy test Fertile patient must use effective contraception No known hypersensitivity E. coli derive proteins No comorbid condition would preclude study PRIOR CONCURRENT THERAPY : Biologic therapy : No prior highdose chemotherapy autologous peripheral blood stem cell transplantation Chemotherapy : See Disease Characteristics See Biologic therapy Endocrine therapy : Not specify Radiotherapy : See Disease Characteristics Surgery : Not specify Other : Recovered prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2004</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>